Dolutegravir news

All news on Dolutegravir (also known as Tivicay and GSK1349572): plants, production capacities, investments and involved companies.

9 June 2026

GSK to acquire Nuvalent for $10.6 billion

Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.

Who will be producing Dolutegravir in the future?

Find out with chemXplore Alpha

Learn more